抗CD30 CAR T细胞作为高危CD30阳性淋巴瘤患者自体造血干细胞移植后巩固治疗的1期研究
这项在美国两个中心开展的1期剂量递增研究纳入21例高危CD30阳性淋巴瘤患者,18例在BEAM方案自体造血干细胞移植后输注抗CD30 CAR T细胞。未观察到剂量限制性毒性,最高测试剂量2×10^8 CAR T细胞/m^2确定为最大耐受剂量。中位随访48.2个月,所有治疗患者中位无进展生存期为32.3个月,霍奇金淋巴瘤患者中位无进展生存期未达到。
要点
- 抗CD30 CAR T细胞移植后巩固治疗未观察到剂量限制性毒性,最大耐受剂量为2×10^8 CAR T细胞/m^2。
- 仅1例发生1级细胞因子释放综合征,无治疗相关死亡。
- 所有治疗患者中位无进展生存期32.3个月,霍奇金淋巴瘤亚组未达到。
核心结论
- 抗CD30 CAR T细胞在BEAM方案和自体造血干细胞移植后作为巩固治疗是安全的,毒性发生率低,在高危复发霍奇金淋巴瘤患者中显示出令人鼓舞的初步活性,作者强调需要更大规模研究来确认这些发现。
研究设计与样本
- 1期剂量递增研究,在美国两个中心开展,计划入组3岁及以上、经免疫组化证实CD30阳性、Karnofsky体能评分>60%、计划行自体造血干细胞移植且被定义为高复发风险(原发难治、初始治疗后12个月内复发或移植前挽救治疗开始时结外受累)的经典型霍奇金淋巴瘤或非霍奇金淋巴瘤患者。
- 2016年6月7日至2020年11月30日共入组21例患者,其中18例(11例霍奇金淋巴瘤、6例T细胞淋巴瘤、1例灰区淋巴瘤)在自体造血干细胞移植后中位22天(范围16-44天)输注抗CD30 CAR T细胞。
- 患者接受单次CAR T细胞输注(2×10^7、1×10^8或2×10^8 CAR T细胞/m^2),在三系造血植入后(定义为中性粒细胞绝对计数≥500细胞/μL持续3天、血小板计数≥25×10^9/L连续5天未输血且血红蛋白≥8 g/dL连续5天未输血)进行。
- 主要终点为确定最大耐受剂量,基于接受CAR T细胞输注患者的剂量限制性毒性发生率;研究注册号ClinicalTrials.gov NCT02663297,入组已完成。
主要发现
- 未观察到剂量限制性毒性,最高测试剂量2×10^8 CAR T细胞/m^2确定为最大耐受剂量。
- 1例患者发生1级细胞因子释放综合征;最常见3-4级不良事件为淋巴细胞减少(2例[11%],共18例)和白细胞减少(2例[11%],共18例);无治疗相关死亡。
- 2例患者在治疗后约2年和2.5年发生第二恶性肿瘤(1例IV期非小细胞肺癌和1例睾丸癌),但判定与治疗无关。
- 输注后中位随访48.2个月(IQR 27.5-60.7),所有治疗患者(n=18)中位无进展生存期为32.3个月(95% CI 4.6个月至不可估计),霍奇金淋巴瘤治疗患者(n=11)中位无进展生存期未达到;所有治疗患者中位总生存期未达到。
局限性
- 作者在结论中强调需要更大规模研究来确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have promising activity when preceded by lymphodepleting chemotherapy. We aimed to determine the safety of anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation (HSCT) in patients with CD30+ lymphoma at high risk of relapse. METHODS: This phase 1 dose-escalation study was performed at two sites in the USA. Patients aged 3 years and older, with classical Hodgkin lymphoma or non-Hodgkin lymphoma with CD30+ disease documented by immunohistochemistry, and a Karnofsky performance score of more than 60% planned for autologous HSCT were eligible if they were considered high risk for relapse as defined by primary refractory disease or relapse within 12 months of initial therapy or extranodal involvement at the start of pre-transplantation salvage therapy. Patients received a single infusion of CAR T cells (2 × 107 CAR T cells per m2, 1 × 108 CAR T cells per m2, or 2 × 108 CAR T cells per m2) as consolidation after trilineage haematopoietic engraftment (defined as absolute neutrophil count ≥500 cells per μL for 3 days, platelet count ≥25 × 109 platelets per L without transfusion for 5 days, and haemoglobin ≥8 g/dL without transfusion for 5 days) following carmustine, etoposide, cytarabine, and melphalan (BEAM) and HSCT. The primary endpoint was the determination of the maximum tolerated dose, which was based on the rate of dose-limiting toxicity in patients who received CAR T-cell infusion. This study is registered with ClinicalTrials.gov (NCT02663297) and enrolment is complete. FINDINGS: Between June 7, 2016, and Nov 30, 2020, 21 patients were enrolled and 18 patients (11 with Hodgkin lymphoma, six with T-cell lymphoma, one with grey zone lymphoma) were infused with anti-CD30 CAR T cells at a median of 22 days (range 16-44) after autologous HSCT. There were no dose-limiting toxicities observed, so the highest dose tested, 2 × 108 CAR T cells per m2, was determined to be the maximum tolerated dose. One patient had grade 1 cytokine release syndrome. The most common grade 3-4 adverse events were lymphopenia (two [11%] of 18) and leukopenia (two [11%] of 18). There were no treatment-related deaths. Two patients developed secondary malignancies approximately 2 years and 2·5 years following treatment (one stage 4 non-small cell lung cancer and one testicular cancer), but these were judged unrelated to treatment. At a median follow-up of 48·2 months (IQR 27·5-60·7) post-infusion, the median progression-free survival for all treated patients (n=18) was 32·3 months (95% CI 4·6 months to not estimable) and the median progression-free survival for treated patients with Hodgkin lymphoma (n=11) has not been reached. The median overall survival for all treated patients has not been reached. INTERPRETATION: Anti-CD30 CAR T-cell infusion as consolidation after BEAM and autologous HSCT is safe, with low rates of toxicity and encouraging preliminary activity in patients with Hodgkin lymphoma at high risk of relapse, highlighting the need for larger studies to confirm these findings. FUNDING: National Heart Lung and Blood Institute, University Cancer Research Fund at the Lineberger Comprehensive Cancer Center.
引用
- Grover NS, Hucks G, Riches ML, et al. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study. Lancet Haematol. 2024. PMID: 38555923. doi:10.1016/S2352-3026(24)00064-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。